Josep M Llovet, MD, PhD is ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine – Hepatic Oncology at the University of Barcelona. Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York). He has published 329 manuscripts in Liver Cancer (citations:85552; h-index:117; IF:6077). Top 1% most cited researcher globally by Clarivate Analytics (2014-21). Major achievement: a) Defining molecular and immune classes of hepatocellular carcinoma (HCC), particularly NASH-HCC, and cholangiocarcinoma (CCA), b) discovery of drivers as therapeutic targets HCC and FGFR2 fusion (CCA) and c) Establishing Standard therapies for HCC, such as sorafenib, regorafenib and ramucirumab. He has been Senior Editor CCR, President of ILCA (2011-13), lectured > 605 international meetings and PI of competitive grants FP7 & Horizon-HEPTROMIC, HEP-CAR, Accelerator Award and NIH R01-award.